Effects of DNA-dependent protein kinase inhibition by NU7026 on DNA repair and cell survival in irradiated gastric cancer cell line N87

Current Oncology

Volumn 21, Issue 2, 2014, Pages 91-96

  Niazi, M T ^a   Mok, G ^a   Heravi, M ^a   Lee, L ^b   Vuong, T ^a   Aloyz, R ^c   Panasci, L ^a   Muanza, T ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

DNA PK inhibitor; Gastric cancer; Nu7026; Radiation therapy; Radiosensitization

Indexed keywords

DNA DEPENDENT PROTEIN KINASE; HISTONE H2AX; NU 7026; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE ASSAY; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IRRADIATION; RADIOSENSITIVITY; STOMACH CANCER;

EID: 84898795574     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.21.1509     Document Type: Article

References (19)

1. Sasako M. Principles of surgical treatment for curable gastric cancer. J Clin Oncol 2003;21(suppl):274s-5s.
2. Gianni L, Panzini I, Tassinari D, Mianulli AM, Desiderio F, Ravaioli A. Meta-analyses of randomized trials of adjuvant chemotherapy in gastric cancer. Ann Oncol 2001;12:1178-80.
3. Allum WH, Hallissey MT, Ward LC, Hockey MS. A controlled, prospective, randomised trial of adjuvant chemotherapy or radiotherapy in respectable gastric cancer: interim report. British Stomach Cancer Group. Br J Cancer 1989;60:739-44.
4. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-30.
5. Jackson SP. Sensing and repairing dna double-strand breaks. Carcinogenesis 2002;23:687-96.
6. De Silva IU, McHugh PJ, Clingen PH, Hartley JA. Defining the roles of nucleotide excision repair and recombination in the repair of dna interstrand cross-links in mammalian cells. Mol Cell Biol 2000;20:7980-90.
7. Collis SJ, DeWeese TL, Jeggo PA, Parker AR. The life and death of dna-pk. Oncogene 2005;24:949-61.
8. Uematsu N, Weterings E, Yano K, et al. Autophosphorylation of dna-pkcs regulates its dynamics at dna double-strand breaks. J Cell Biol 2007;177:219-29.
9. Weterings E, Chen DJ. The endless tale of non-homologous end-joining. Cell Res 2008;18:114-24.
10. Salles B, Calsou P, Frit P, Muller C. The dna repair complex dna-pk, a pharmacological target in cancer chemotherapy and radiotherapy. Pathol Biol (Paris) 2006;54:185-93.
11. Veuger SJ, Curtin NJ, Richardson CJ, Smith GC, Durkacz BW. Radiosensitization and dna repair inhibition by the combined use of novel inhibitors of dna-dependent protein kinase and poly (adp-ribose) polymerase-1. Cancer Res 2003;18:6008-15.
12. Amrein L, Loignon M, Goulet AC, et al. Chlorambucil cytotoxicity in malignant B lymphocytes is synergistically increased by 2-(morpholin-4-yl)-benzo[h]chomen-4-one (NU7026)-mediated inhibition of dna double-strand break repair via inhibition of dnadependent protein kinase. J Pharmacol Exp Ther 2007;321:848-55.
13. Muslimovic A, Ismail IH, Gao Y, Hammarsten O. An optimized method for measurement of gamma-H2AX in blood mononuclear and cultured cells. Nat Protoc 2003;3:1187-93.
14. Huang X, Darzynkiewicz Z. Cytometric assessment of histone H2AX phosphorylation: a reporter of dna damage. Methods Mol Biol 2006;314:73-80.
15. Mukherjee B, McEllin B, Camacho CV, et al. egfrviii and dna double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res 2009;69:4252-9.
16. Yang C, Betti C, Singh S, Toor A, Vaughan A. Impaired nehj function in multiple myeloma. Mutat Res 2009;660:66-73.
17. Nutley BP, Smith NF, Hayes A, et al. Preclinical pharmacokinetics and metabolism of a novel prototype dna-pk inhibitor NU7026. Br J Cancer 2005;93:1011-18.
18. Willmore E, de Caux S, Sunter NJ, et al. A novel dnadependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase ii poisons used in the treatment of leukemia. Blood 2004;103:4659-65.
19. Zhu H, Gooderham NJ. Mechanisms of induction of cell cycle arrest and cell death by cryptolepine in human lung adenocarcinoma A549 cells. Toxicol Sci 2006;91:132-9.